Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study

BACKGROUND: The 2024 McDonald criteria for multiple sclerosis incorporate optic nerve lesions as a fifth topography for dissemination in space, and other additional diagnostic features. We evaluated their performance in patients with acute optic neuritis, a common first manifestation of multiple sclerosis. METHODS: In this cross-sectional cohort analysis from the prospective, multicentre Acute Optic Neuritis Network (ACON) study, we compared the 2024 and 2017 McDonald criteria for multiple sclerosis in patients with a first documented presentation of optic neuritis from 25 centres in 17 countries across six continents. The cohort included patients with idiopathic optic neuritis, clinically isolated syndrome (CIS) according to 2017 McDonald criteria, multiple sclerosis according to 2017 McDonald criteria, aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). We assessed the sensitivity of the 2017 and 2024 McDonald criteria for diagnosis of multiple sclerosis using data from patients diagnosed, according to the 2017 McDonald criteria, with CIS (defined by presence of MRI lesions in typical locations suggestive of multiple sclerosis or presence of oligoclonal bands) or multiple sclerosis. Specificity was measured with data from the AQP4-IgG-positive NMOSD and MOGAD cohorts. FINDINGS: Between Aug 21, 2020, and Dec 31, 2025, 421 patients were enrolled in ACON. After exclusion of patients with missing information on diagnosis and MRI data, 310 were included in this analysis (59 with idiopathic optic neuritis, 85 with CIS according to 2017 criteria, 85 with multiple sclerosis according to 2017 criteria, 22 with AQP4-IgG-positive NMOSD, and 59 with MOGAD). All patients with multiple sclerosis according to the 2017 McDonald criteria (85 [100%] of 85) fulfilled the 2024 criteria and 27 (32%) of 85 patients with CIS according to the 2017 McDonald criteria were diagnosed as having multiple sclerosis according to the 2024 criteria. Additionally, three (14%) of 22 people with AQP4-IgG-positive NMOSD and six (10%) of 59 people with MOGAD met the 2024 McDonald criteria for multiple sclerosis. The sensitivity of the 2017 criteria was 50% (95% CI 42-58), compared with 66% (95% CI 58-73) for the 2024 criteria, for identification of people with multiple sclerosis among those presenting with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 criteria. Specificity of the 2017 criteria was 100% (95% CI 96-100) and that of the 2024 criteria was 89% (95% CI 80-95); diagnostic accuracy of the 2017 criteria was 66% (95% CI 60-72) and that of the 2024 criteria was 73% (95% CI 67-79). INTERPRETATION: In our cohort of patients with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 McDonald criteria, the 2024 McDonald criteria enhanced diagnostic sensitivity for multiple sclerosis in people with optic-neuritis-related CIS, potentially enabling earlier diagnosis of multiple sclerosis. However, the criteria reduced specificity in people with optic neuritis related to AQP4-IgG-positive NMOSD and MOGAD, highlighting the need for careful exclusion of alternative diagnoses and further real-world validation. FUNDING: Roche.

Authors

Institutions

Publication Details

Journal
The Lancet Neurology
Published
2026-11-18
DOI
https://doi.org/10.1016/s1474-4422(26)00352-2
Citations
1
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
2.62

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study

Matteo Gastaldi, Frank Konietschke, Natthapon Rattanathamsakul, Francesca Bosello et al.
1 citations
The Lancet Neurology
Multiple Sclerosis Research Studies
2.62
article

Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study

Matteo Gastaldi, Frank Konietschke, Natthapon Rattanathamsakul, Francesca Bosello, Ti Wu, Susanna Asseyer, Sara Samadzadeh, Jaume Sastre‐Garriga, Philipp Klyscz, Pia S. Sperber, Sol Zamir, Ricardo Nicolás Alonso, Charlotte Bereuter, Itay Lotan, Sara Carta, Iliya Simantov, Luca Bollo, María Belén Luis, Jana Lízrová Preiningerová, Adi Wilf‐Yarkoni, Edgar Carnero Contentti, Jeffrey L. Bennett, Thivya Pakeerathan, Sasitorn Siritho, Lekha Pandit, Jessy Chen, Christoph Heesen, Maja Olszewska, Joachim B. Havla, Nanthaya Tisavipat, Netta Levin, Jonathan A. Gernert, Eser Buluş, Christina Mayer, Russell Clive Dale, Friedemann Paul, Ángela Vidal‐Jordana, Josep O. Dalmau, Tianrong Yeo, Hanna Gwendolyn Zimmermann, Frederike Cosima Oertel, Hadas Stiebel‐Kalish, Mark Andrew Hellmann, Bernardo F. Sánchez-Dalmau, Ayşe Altıntaş, Sudarshini Ramanathan, Sara Mariotto, Cassandra Ocampo, Yamit Cohen‐Tayar, Anne‐Katrin Pröbstel, Jyh Yung Hor, Adi Vaknin‐Dembinsky, Ilya Ayzenberg, Sean Joseph Pittock, Michael Levy, Fu‐Dong Shi, Yolanda Blanco, Giacomo Greco, Jacqueline A. Palace, Aviv Fineberg, Cohen Leila, Hanna Zausinger, Azzam Ghaben, Fiona Chan, Axel Petzold, Atira Bick, Pablo López, Kelvin Li Zhenghao, Luis Alfonso Zarco, Isabel Torres, Omer Bialer, Alvaro Jose Mejia Vergara, Eoin P. Flanagan, Yihan Wang, John J Chen, Jemal Shifa, Nadège Leprêtre, Carlos Alvarado, José Luis Peralta-Uribe
article en
1 citations

Abstract

BACKGROUND: The 2024 McDonald criteria for multiple sclerosis incorporate optic nerve lesions as a fifth topography for dissemination in space, and other additional diagnostic features. We evaluated their performance in patients with acute optic neuritis, a common first manifestation of multiple sclerosis. METHODS: In this cross-sectional cohort analysis from the prospective, multicentre Acute Optic Neuritis Network (ACON) study, we compared the 2024 and 2017 McDonald criteria for multiple sclerosis in patients with a first documented presentation of optic neuritis from 25 centres in 17 countries across six continents. The cohort included patients with idiopathic optic neuritis, clinically isolated syndrome (CIS) according to 2017 McDonald criteria, multiple sclerosis according to 2017 McDonald criteria, aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). We assessed the sensitivity of the 2017 and 2024 McDonald criteria for diagnosis of multiple sclerosis using data from patients diagnosed, according to the 2017 McDonald criteria, with CIS (defined by presence of MRI lesions in typical locations suggestive of multiple sclerosis or presence of oligoclonal bands) or multiple sclerosis. Specificity was measured with data from the AQP4-IgG-positive NMOSD and MOGAD cohorts. FINDINGS: Between Aug 21, 2020, and Dec 31, 2025, 421 patients were enrolled in ACON. After exclusion of patients with missing information on diagnosis and MRI data, 310 were included in this analysis (59 with idiopathic optic neuritis, 85 with CIS according to 2017 criteria, 85 with multiple sclerosis according to 2017 criteria, 22 with AQP4-IgG-positive NMOSD, and 59 with MOGAD). All patients with multiple sclerosis according to the 2017 McDonald criteria (85 [100%] of 85) fulfilled the 2024 criteria and 27 (32%) of 85 patients with CIS according to the 2017 McDonald criteria were diagnosed as having multiple sclerosis according to the 2024 criteria. Additionally, three (14%) of 22 people with AQP4-IgG-positive NMOSD and six (10%) of 59 people with MOGAD met the 2024 McDonald criteria for multiple sclerosis. The sensitivity of the 2017 criteria was 50% (95% CI 42-58), compared with 66% (95% CI 58-73) for the 2024 criteria, for identification of people with multiple sclerosis among those presenting with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 criteria. Specificity of the 2017 criteria was 100% (95% CI 96-100) and that of the 2024 criteria was 89% (95% CI 80-95); diagnostic accuracy of the 2017 criteria was 66% (95% CI 60-72) and that of the 2024 criteria was 73% (95% CI 67-79). INTERPRETATION: In our cohort of patients with a first episode of optic neuritis attributed to multiple sclerosis or CIS according to the 2017 McDonald criteria, the 2024 McDonald criteria enhanced diagnostic sensitivity for multiple sclerosis in people with optic-neuritis-related CIS, potentially enabling earlier diagnosis of multiple sclerosis. However, the criteria reduced specificity in people with optic neuritis related to AQP4-IgG-positive NMOSD and MOGAD, highlighting the need for careful exclusion of alternative diagnoses and further real-world validation. FUNDING: Roche.

The Lancet NeurologyVol. 25(12)
University of Verona (IT), Concord Hospital (US), Mayo Clinic (US), Siriraj Hospital (TH), Nitte University (IN), Koç University (TR), University of Botswana (BW), Tel Aviv University (IL), Nanyang Technological University (SG), University of Basel (CH), Max Delbrück Center (DE), Pontificia Universidad Javeriana (CO), Mahidol University (TH), Bumrungrad International Hospital (TH), Hadassah Medical Center (IL), Concord Repatriation General Hospital (AU), Rabin Medical Center (IL), Tianjin Medical University General Hospital (CN), University Hospital of Basel (CH), LMU Klinikum (DE), Humboldt-Universität zu Berlin (DE), Einstein Center Digital Future (DE), Hospital Ramos Mejía (AR), University Medical Center Hamburg-Eppendorf (DE), Centro de Investigación Biomédica en Red (ES), Duke-NUS Medical School (SG), Vall d'Hebron Hospital Universitari (ES), National Neuroscience Institute (SG), St. Josef-Hospital (DE), Hospital Alemán (AR), Moorfields Eye Hospital (GB), National Hospital for Neurology and Neurosurgery (GB), Hospital Universitario San Ignacio (CO), General University Hospital in Prague (CZ), Centre d'Esclerosi Múltiple de Catalunya (ES), Institut für Klinische Neuroimmunologie (DE), Institute of Neuroimmunology and Multiple Sclerosis (DE), Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (TR), University College London (GB), University of Colorado Anschutz Medical Campus (US), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), Ruhr University Bochum (DE), University of Colorado Denver (US)
Roche
Good health and well-being
Openalex Percentile: Top 18%
Multiple Sclerosis Research Studies
2.62
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon